Barclays analyst Matt Miksic upgraded ZimVie (ZIMV) to Equal Weight from Underweight with a price target of $19, up from $9, after the company agreed to be taken private by Archimed for $19.00 per share. The firm cites the proposed deal for the upgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZIMV: